{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-003394","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2022-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.181085+00:00","generated_at":"2026-06-27T18:48:02.485206+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vericel estimates FY2021 revenue growth 25-26%, adj. EBITDA ~$30M, cash ~$129M","bullets":["Preliminary FY2021 revenue growth of 25%-26% (unaudited); total adjusted EBITDA ~$30M.","Cash and investments as of Dec 31, 2021 ~$129M.","Company presented at 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022.","Financial results are preliminary and subject to change upon audit."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-003394","json":"https://secwatch.observer/filing/0001104659-22-003394.json","markdown":"https://secwatch.observer/filing/0001104659-22-003394.md","text":"https://secwatch.observer/filing/0001104659-22-003394.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000110465922003394/0001104659-22-003394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000110465922003394/tm222643d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T18:48:02.485206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}